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doi:10.1016/j.jmii.2011.01.017Background: Acinetobacter baumannii has emerged as an important pathogen of nosocomial
infection. The aim of this study was to evaluate the predictors of poor outcome in surgical
patients with A baumannii bacteremia.
Methods: We retrospectively recruited a total of 50 patients who developed A baumannii
bacteremia within 2 weeks after surgery during a 113-month period. The primary outcome
for this study was all-cause 14-day mortality. Clinical and laboratory data, antimicrobial
susceptibility, treatment, and Sequential Organ Failure Assessment (SOFA) score were evalu-
ated as possible predictors of outcome.
Results: The 14-day mortality was 20% and there was no association between type of surgery and
mortality. The SOFA score was the only independent predictor of 14-day mortality after adjust-
ment for other variables. The calibration was acceptable (Hosmer-Lemeshow c2 Z 3.65,
p Z 0.72) and the discrimination was good (area under the receiver operating characteristic
curve: 0.80  0.07, 95% confidence interval, 0.67e0.94). We found that a SOFA score 7 was
a significant predictor of 14-day mortality in surgical patients with A baumannii bacteremia.
Conclusions: The SOFA score assessed at the onset of bacteremia is a reliable tool for predicting
14-day mortality in surgical patients with A baumannii bacteremia.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2,
.tw (T.-L. Chen).
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method. A reference strain of Escherichia coli ATCC 25922Acinetobacter baumannii is an aerobic, nonfermentative,
gram-negative coccobacillus that is widespread in the natural
environment.1,2 It has emerged as an important pathogen of
nosocomial infection and has caused epidemic outbreaks in
recent years.3,4,5 Its rapid acquisition of a wide variety of
antibiotic resistance genes has caused serious therapeutic
problemsworldwide.6Abaumannii is associatedwithavariety
of serious infections in the hospital setting, especially in
patients staying in intensive care units,7 in immunosuppressed
hosts,8,9 and in burn patients.7 The mortality rate associated
withAbaumannii bacteremia ranges from17% to 63%.9,10,11,12
Factors independently associated with poor prognosis of
patients with A baumannii bacteremia include pneumonia as
the source of bacteremia, presence of septic shock, dissemi-
nated intravascular coagulation, mechanical ventilator use,
acute renal failure, inappropriate antibiotic therapy, and
recent surgery.9,12,13,14
Surgical patients are at high risk of developing a hospital-
acquired infection15 including A baumannii bacteremia. The
aim of this study was to evaluate the predictors of poor
outcome in surgical patients with A baumannii bacteremia.Methods
Hospital setting and study population
Subjects in this retrospective study comprised surgical
patients with 2-week postoperative blood cultures positive for
A baumannii at the Taipei Veterans General Hospital, a 2,900-
bed tertiary medical center in northern Taiwan, during the
period June 1998 to November 2007. Patients with poly-
microbial infections inadditiontoAbaumanniiwereexcluded.
Patient characteristics, underlying diseases, types of surgeries
(based on the International Classification of Diseases, Ninth
Revision, Clinical Modification), invasive procedures, clinical
and laboratory data, antimicrobial susceptibility, treatment,
and outcomes were obtained from medical records. The
Sequential Organ Failure Assessment (SOFA) score was calcu-
lated based on data that had been gathered and recorded at
the onset of A baumannii bacteremia. Patients with missing
values for the calculation of SOFA scores were excluded. The
primary study outcome was all-cause 14-day mortality.
Identification and antimicrobial susceptibility
testing
The A baumannii isolates had been phenotypically identified
by ID 32 GN (Biomerieux, St. Louis, MO, USA) and verified to
the genomic species level as A baumannii (genomic species 2)
by a multiplex polymerase chain reaction method.16 The
antimicrobial agents tested were as follows: amikacin, sul-
bactam, ceftazidime, ciprofloxacin, cefepime, colistin,
gentamicin, imipenem, trimethoprim/sulfamethoxazole, and
piperacillin/tazobactam. The minimal inhibitory concentra-
tions of sulbactam, colistin, and imipenemwas determinedby
the agar dilution method and interpreted according to the
Clinical Laboratory Standards Institute guidelines;17 the rest
of other antibiotics were performed by the disc diffusionand Pseudomonas aeruginosa ATCC 27853 was used as
the control. Multidrug-resistant A baumannii (MDRAB) was
defined if the isolate was resistant to three or more classes of
antimicrobial agents (including amikin, sulbactam, ceftazi-
dime, ciprofloxacin, cefepime, colistin, gentamicin, imipe-
nem, trimethoprim/sulfamethoxazole, and piperacillin/
tazobactam). Extensively drug-resistant A baumannii was
defined if the isolate was resistant to all commercially avail-
able antimicrobial agents except for colistin and tigecycline.
Definitions
The definition of a surgical patient is someone who had
operative procedures performed in the operation rooms.
A baumannii bacteremia was diagnosed in patients with
clinical evidence of infection (such as fever, chills, rigor,
leukocytosis, elevated C-reactive protein, or sepsis) and
one or more blood isolates of A baumannii at the same
time.12 The date of the first positive blood culture was
considered the onset of A baumannii bacteremia, and the
survival time was calculated from the onset of bacteremia.
The origin of bacteremia was determined when a specific
focus of infection was identified during the bacteremia
episode. Pneumonia was defined if there was isolation of A
baumannii from pulmonary secretion with concurrent
infiltrates on chest radiography and clinical signs and
symptoms of infection. Central venous catheter infection
was defined if there was isolation of A baumannii from tip
cultures with concurrent clinical signs and symptoms.
Urinary tract infection was defined if there was isolation of
A baumannii from urine cultures with urinalysis demon-
strating pyuria. Wound infection was defined based on the
clinical judgment of the treating physicians along with an
isolation of A baumannii from the wound. Intra-abdominal
infection was defined if there was isolation of A baumannii
from specimen obtained from the intra-abdominal cavity.18
End-stage renal disease was defined as a creatinine
clearance rate <5 mL/min that required hemodialysis.
Immunosuppressive status was defined in patients with one
or more of the following: solid organ or stem cell trans-
plantation, human immunodeficiency virus infection, or
treatment with cytotoxic chemotherapy within the previous
6 weeks or more than two doses of steroid or other immu-
nosuppressive agents within 2 weeks before the first episode
of A baumannii bacteremia.12 Shock was defined according
to the American College of Chest Physicians-Society of
Critical Care Medicine consensus conference as evidence
of organ hypoperfusion, and either a systolic blood pressure
of <90 or >30 mmHg less than baseline values, or the need
for vasopressor/inotropes to maintain blood pressure despite
adequate fluid resuscitation.19 Appropriate antimicrobial
therapy was defined as treatment with at least one antibi-
otic that had in vitro activity against the pathogen and
administered within 2 days on the date of the blood culture
obtained, with correct dosage, and with the use of at least
48 hours; otherwise, it was defined as “inappropriate”.
Statistical analysis
Patients were stratified into two groups according to survival
status on Day 14 after the first positive blood culture had been
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mean  standard deviation and categorical variables are
expressed as a percentage of the total number of patients
analyzed. c2 test with Yates’ correction or Fisher’s exact test
was used for categorical variables, and Student t test orMann-
Whitney rank sum test was used to compare continuous
variables as appropriate. The survival curve was plotted by
means of the Kaplan-Meier method. Variables with a p value
<0.1 in the univariate analysis were included in a multiple
logistic regression model.
The area under the receiver operating characteristic
curve was used to test the discrimination ability of the SOFA
score.20,21 We used Hosmer-Lemeshow c2 goodness of fit (C
statistic) to assess the calibration by comparing the observed
mortality rate with the predictedmortality rate.22 A small c2
value suggested good calibration.
All tests were 2-tailed. A p value less than 0.05 was
considered to represent statistical significance. All statis-
tical analyses were performed with the statistical package
SPSS for Windows (Version 17, SPSS Inc., Chicago, IL, USA).Results
During the study period, there were approximately 373,100
patients receivedoperativeprocedures in theoperation rooms
in our hospital. A total of 179 patients suffered from symp-
tomatic bacteremia because of Acinetobacter calcoaceticus-
baumannii complex within 2 weeks after having undergone
surgery. Among them, 71 episodes of bacteremia because of A
baumannii genomic species 2 were identified. After excluding
theduplicatedepisodesand thosewithmissingdata,wefinally
recruited50patients inourstudy.Therewere17(34%)patients
underwent thoracoabdominal surgeries [intra-abdominal
surgery (nZ 15), heart surgery (nZ 1), lung surgery (nZ 1)]
and 33 (66%) patients underwent nonthoracoabdominal
surgeries [tracheostomy (n Z 15), permanent catheter
implantation (n Z 6), orthopedic surgery (n Z 4), wound
debridement (n Z 3), brain surgery (n Z 2), genitourinary
tract surgery (nZ 2), thyroidectomy (nZ 1)]. There was no
significant difference in mortality between patients who
received thoracoabdominal surgeries and those who received
nonthoracoabdominal surgeries (mortality rate 29.4% vs.
15.2%, p Z 0.277). The mean age of our study patients was
73.0  17.1 (mean  standard deviation) years and 39 (78%)
patientsweremale. Therewas no statistical difference on age
or gender among survivors and nonsurvivors (data not shown).
The overall mortality rate was 20% at 14 days and 36% at 30
days, and the in-hospital mortality was 48%.
Patient characteristics, underlying conditions, and
disease-related characteristics are listed in Table 1. The
number of underlying comorbid conditions or the number of
invasive procedures before bacteremia onset was not signifi-
cantly associated with the prognosis (data not shown).
The origin of bacteremia was undetermined in 15 (30%)
patients. The most common primary origin was pneumonia
(50%) followed by central venous catheter infection (32%),
and urinary tract infection (12%). Only three (6%) patients had
A baumannii bacteremia because of postoperative wound
infection and all of them survived. Multiple origins of
bacteremia (2) were identified in 14 (28%) patients. Among
them, three patients had three sources of bacteremia (onepatient had pneumonia, central venous catheter infection,
and urinary tract infection, one patient had pneumonia,
central venous catheter infection, and intra-abdominal
infection, and the other one had pneumonia, central venous
catheter infection, andwound infection); all of them survived
in 14 days. The other 11 patients had two sources of bacter-
emia (7 patients had pneumonia combined with central
venous catheter infections, 4 patients had pneumonia
combined with other site of infections such as urine, wound,
and intra-abdominal infections). There was no significant
difference in 14-day mortality between patients with single-
origin and patients with multiple-origin bacteremia.
Results of in vitro antimicrobial susceptibility tests are
shown in Table 2. Colistin was the most active agent (100%
susceptible), followed by imipenem (72%), sulbactam (44%),
and cefepime (38%). Of the 14 imipenem nonsusceptible
isolates, 2 were susceptible to sulbactam, 2 were susceptible
to cefepime, 2 were susceptible to piperacillin/tazobactm, 1
was susceptible to trimethoprim/sulfamethoxazole, and the
other 7 isolates were extensively drug-resistant A baumannii.
There was no significant difference in mortality between
patients with bacteremia caused by carbapenem-resistant A
baumannii (CRAB) or MDRAB and patients with bacteremia
because of carbapenem-susceptible or non-MDR isolates
(mortality rate of CRAB vs. non-CRAB: 22.2% vs. 19.5%,
p Z 0.845; mortality rate of MDRAB vs. non-MDRAB: 20% vs.
20%, p Z 1.000). Empiric antimicrobial therapy was admin-
istered in 43 (86%) patients at bacteremia onset, but was
appropriate in only 10 (23.3%) of them. The rates of appro-
priate antimicrobial therapy within 2 days are lower in the
CRAB and MDRAB groups, but without significant difference
(CRAB vs. non-CRAB: 11.1% vs. 43.9%, pZ 0.066; MDRAB vs.
non-MDRAB: 35% vs. 50%, pZ 0.382).
Significant predictors of 14-day mortality in the univar-
iate analysis included inappropriate antimicrobial therapy
administered within 2 days of bacteremia onset [odds ratio
(OR), 9; 95% confidence interval (CI), 1.15e86.01] and SOFA
score (OR, 1.25; 95% CI, 1.00e1.44). Multivariate analysis
revealed that SOFA score was the only independent
predictor of 14-day mortality (OR, 1.20; 95% CI, 1.00e1.44).
The calibration was acceptable (Hosmer-Lemeshow
c2Z 3.65, pZ 0.72) and discrimination was excellent (area
under the receiver operating characteristic curve:
0.80  0.07, 95% CI, 0.67e0.94, pZ 0.003) for SOFA score in
predicting 14-daymortality (Fig. 1). The cut-off pointwith the
best sensitivity and specificity was a SOFA score >7
(sensitivity: 70, specificity 71). Kaplan-Meier survival curve
showed that a SOFA score >7 was significantly predictive of
14-day mortality in surgical patients with A baumannii
bacteremia (pZ 0.024) (Fig. 2).Discussion
Infections caused by A baumannii are of great concern
worldwide. Although many studies on A baumannii
bacteremia have been reported, most have involved pop-
ulations with both monomicrobial and polymicrobial
infections.23 Therefore, we selected surgical patients with
monomicrobial bacteremia. To the best of our knowledge,
this is the first retrospective study to provide detailed
epidemiological characteristics and outcomes of
Table 1 Demographic and disease-related characteristics in surgical patients with Acinetobacter baumannii bacteremia
according to 14-day survival status
Patient characteristics Alive (n Z 40)a Dead (n Z 10)a Total (n Z 50)a p
Underlying condition
Alcoholism 4 (10) 3 (30) 7 (14) 0.133
Chronic renal insufficiency 6 (15) 2 (20) 8 (16) 0.653
Chronic obstructive pulmonary disease 5 (12.5) 0 (0) 5 (10) 0.569
Coronary artery disease 10 (25) 3 (30) 13 (26) 0.707
Hypertension 7 (17.5) 3 (30) 10 (20) 0.397
Immunosuppressive status 23 (57.5) 4 (40.0) 27 (54.0) 0.480
Old cerebral vascular accident 3 (7.5) 3 (30) 6 (12) 0.086
Smoking 8 (20) 4 (40) 12 (24) 0.225
Solid tumor 15 (37.5) 2 (20) 17 (34) 0.461
Type 2 diabetes mellitus 9 (22.5) 2 (20) 11 (22) 1.000
Invasive procedures before bacteremia onset
Abdominal drain 9 (22.5) 3 (30) 12 (24) 0.686
Central venous catheter 32 (80) 9 (90) 41 (82) 0.665
Hemodialysis 4 (10) 1 (10) 5 (10) 1.000
Infusion of total parenteral nutrition 5 (12.5) 3 (30) 8 (16) 0.331
Mechanical ventilation 25 (62.5) 9 (90) 34 (68) 0.138
Origins of bacteremia
Pneumonia 21 (52.5) 4 (40) 25 (50) 0.725
Central venous catheter infection 15 (37.5) 1 (10) 16 (32) 0.198
Unknown 10 (25) 5 (50) 15 (30) 0.247
Urinary tract infection 5 (12.5) 1 (10) 6 (12) 1.000
Postsurgical wound infection 3 (7.5) 0 (0) 3 (6) 0.882
Intra-abdominal infection 2 (5) 1 (10) 3 (6) 1.000
Origins > 2 12 (30) 2 (20) 14 (24) 1.000
ICU stay at bacteremia onset 22 (55) 6 (60) 28 (56) 1.000
Inappropriate empiric antimicrobial therapy
at bacteremia onset
29 (72.5) 10 (100) 39 (78) 0.092
Inappropriate antimicrobial therapy within 2 d 20 (50) 9 (90) 29 (58) 0.031
MDRAB 32 (80) 8 (80) 40 (80) 1.000
CRAB 7 (17.5) 2 (20) 9 (18) 1.000
Shock within 1 wk 13 (32.5) 5 (50) 18 (36) 0.463
SOFA score 4.9  4.3 9.3  4.0 5.8  4.5 0.005
a Data are presented as n (%) or mean  SD.
CRAB Z carbapenem-resistant Acinetobacter baumannii; ICU Z intensive care unit; MDRAB Z multidrug-resistant Acinetobacter
baumannii; SD Z standard deviation; SOFA Z sequential organ failure assessment.
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bacteremia.
In our study, the 14-daymortality rate was 20% and the 30-
day mortality rate was 36%. The origin of bacteremia, the
number of co-morbidities, and the number of invasive
procedures before bacteremia onset were not significantly
associated with 14-day mortality. Although CRAB and inap-
propriate antimicrobial therapy administered within 2 days
have the trend toward poor outcome, we are unable to prove
that these factors are significant predictors of increased
mortality. Thismay bebecause of the small patient number of
the present investigation. In our study, all isolates were
susceptible to colistin. Because of concerns about the serum
concentration of colistin, some authors have proposed that
colistin be reserved for salvage therapy rather than being
routinely administered as a first-line therapy.24 Prospective
clinical trials are warranted to evaluate the usefulness ofcolistin as part of empirical antimicrobial therapy in patients
suspected of having MDRAB bacteremia. New antimicrobial
agents are also urgently needed for the treatment of carba-
penem-resistant A baumannii infections.
We used the SOFA score to assess the severity of illness.
The SOFA score is a well-validated method by which to
measure the severity of organ dysfunction.25,26 The total
score consists of components of six major organ systems and
a high-SOFA score for any individual organ system is
associated with increased mortality. The reason we used the
SOFA score instead of other scoring systems is because
the SOFA score is easier to calculate. Although we found that
the SOFA score is a good predictor of outcome of surgical
patients with A baumannii, it should be noted that we used
one-time scoring at bacteremia onset rather than serial
scoring. Ferreira et al.27 reported that the use of serial SOFA
scores provides a more effective representation of the
Table 2 Antimicrobial susceptibility of Acinetobacter baumannii isolates determined by agar dilution and disc diffusion
methods
Antimicrobial agenta MIC (mg/mL) No. of isolates (%)
Range MIC50 MIC90 Susceptible Intermediately resistant Resistant
Colistin 0.25e2 1 2 50 (100) 0 (0) 0 (0)
Imipenem 0.25e32 2 32 36 (72) 4 (8) 10 (20)
Sulbactam 1 to >64 16 64 22 (44) 5 (10) 23 (46)
Cefepime 19 (38) 9 (18) 22 (44)
Amikacin 12 (24) 1 (2) 37 (74)
Ceftazidime 10 (20) 0 (0) 40 (80)
Gentamicin 10 (20) 0 (0) 40 (80)
Ciprofloxacin 9 (18) 2 (0) 29 (58)
Piperacillin-tazobactam 9 (18) 10 (20) 31 (62)
Trimethoprim-sulfamethoxazole 6 (12) 0 (0) 44 (88)
a MICs of colistin, imipenem, and sulbactam were performed by agar dilution method; cefepime, amikacin, ceftazidime, gentamicin,
ciprofloxacin, piperacillin-tazobactam, and trimethoprim/sulfamethoxazole were performed by disc diffusion method.
MIC Z minimum inhibitory concentration; MIC50 Z minimum concentration inhibiting 50% of isolates; MIC90 Z minimum concentration
inhibiting 90% of isolates.
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laborious. For clinicians, the use of a one-time scoring system
is much easier and more practical.
Univariate analysis showed that administration of inap-
propriate antimicrobial agents within 2 days of A baumannii
bacteremia onset was associated with increased mortality;
however, it was not a significant predictive variable when
we controlled for SOFA score. This result may be partly
explained by the fact that the severity of illness has a larger
impact on 14-day mortality than discordant antimicrobialFigure 1. Receiver operating characteristic plot of 14-day
mortality predictions using the SOFA score for 50 surgical patients
with Acinetobacter baumannii bacteremia. CI Z confidence
interval; AUROCZ area under the receiver operating character-
istic curve; SOFAZ sequential organ failure assessment.therapy. We also found that SOFA score >7 is associated
with a higher 14-day mortality. This finding may help
clinicians to identify patients at high risk of death.
In conclusion, the present study is unique in evaluating
factors predictive of mortality among surgical patients with
monomicrobial bacteremia caused by A baumannii. The SOFA
score obtained at bacteremia onsetwas the only independent
predictor ofmortality. This result highlights the importance of
severity of illness in the outcome of A baumannii bacteremia
in this patient group. However, the impacts of inappropriate
antimicrobial therapy and antibiotic resistant strains are not
negligible and should, therefore, be verified by further
prospective and randomized studies.Figure 2. Survival curve for surgical patients with Acineto-
bacter baumannii bacteremia. Kaplan-Meier survival analysis
showed a significantly reduced 14-day survival rate for patients
with SOFA >7. SOFA Z sequential organ failure assessment.
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